evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,667 questions · 21,760 findings · 2,177 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 4,173 · 19.2%GRADE not reported 2,300 · 10.6%Very low 5,276 · 24.2%Low 5,764 · 26.5%Moderate 3,298 · 15.2%High 949 · 4.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Betamethasone acetate plus phosphate vs betamethasone phosphate – fetal/neonatal outcomes

Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth

It is very uncertain whether betamethasone acetate plus phosphate changes any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone acetate plus phosphate vs betamethasone phosphate – fetal/neonatal outcomes

Respiratory distress syndrome · women at risk of preterm birth

It is very uncertain whether betamethasone acetate plus phosphate changes respiratory distress syndrome compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone acetate plus phosphate vs betamethasone phosphate – fetal/neonatal outcomes

Intraventricular haemorrhage · women at risk of preterm birth

It is very uncertain whether betamethasone acetate plus phosphate changes intraventricular haemorrhage compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes any known death after randomisation (fetal, neonatal, child, child… compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Respiratory distress syndrome · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes respiratory distress syndrome compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Intraventricular haemorrhage · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes intraventricular haemorrhage compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Chronic lung disease · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes chronic lung disease compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Necrotising enterocolitis · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes necrotising enterocolitis compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Dexamethasone vs betamethasone – maternal outcomes

Maternal adverse effects of therapy · women at risk of preterm birth

Dexamethasone showed no clear difference in maternal adverse effects of therapy compared with betamethasone – maternal outcomes (moderate certainty).

1 finding from 1 review

Dexamethasone vs betamethasone – child outcomes

Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth

Dexamethasone showed no clear difference in any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone – fetal/neonatal outcomes (moderate certainty).

1 finding from 1 review